Literature DB >> 25530552

Development and testing of a tool to assess patient preferences for phase I clinical trial participation.

Rebecca D Pentz1,2, Kristopher A Hendershot1, Louisa Wall1, Taylor E White2, Susan K Peterson3, Cheryl B Thomas4, Jennifer McCormick4, Michael J Green5, Colleen Lewis6, Zachary Luke Farmer7, Fay J Hlubocky8, Tehseen Dossul9, Margie D Dixon1, Yuan Liu2, Jeffrey M Switchenko2, Carolina Salvador7, Taofeek K Owonikoko1,2, R Donald Harvey1,2, Fadlo R Khuri1,2.   

Abstract

Entities:  

Keywords:  End-Stage Cancer; Patient Preferences; Phase I Trials; Physician Recommendation; Reearch Ethics

Mesh：

Year:  2014        PMID： 25530552      PMCID： PMC4474780          DOI： 10.1002/pon.3731

Source DB:  PubMed          Journal:  Psychooncology        ISSN： 1057-9249            Impact factor:   3.894


× No keyword cloud information.
  10 in total

Review 1.  Interventions to improve research participants' understanding in informed consent for research: a systematic review.

Authors:  James Flory; Ezekiel Emanuel
Journal:  JAMA       Date:  2004-10-06       Impact factor: 56.272

2.  Patients rate physician communication about lung cancer.

Authors:  Judith E Nelson; Elizabeth B Gay; Andrew R Berman; Charles A Powell; John Salazar-Schicchi; Juan P Wisnivesky
Journal:  Cancer       Date:  2011-04-14       Impact factor: 6.860

3.  Identifying patient information needs about cancer clinical trials using a Question Prompt List.

Authors:  Richard F Brown; Elyse Shuk; Phyllis Butow; Shawna Edgerson; Martin H N Tattersall; Jamie S Ostroff
Journal:  Patient Educ Couns       Date:  2010-08-02

4.  American society of clinical oncology statement: toward individualized care for patients with advanced cancer.

Authors:  Jeffrey M Peppercorn; Thomas J Smith; Paul R Helft; David J Debono; Scott R Berry; Dana S Wollins; Daniel M Hayes; Jamie H Von Roenn; Lowell E Schnipper
Journal:  J Clin Oncol       Date:  2011-01-24       Impact factor: 44.544

5.  Accuracy of primary care and hospital-based physicians' predictions of elderly outpatients' treatment preferences with and without advance directives.

Authors:  K M Coppola; P H Ditto; J H Danks; W D Smucker
Journal:  Arch Intern Med       Date:  2001-02-12

6.  More talk, less paper: predicting the accuracy of substituted judgments.

Authors:  D P Sulmasy; K Haller; P B Terry
Journal:  Am J Med       Date:  1994-05       Impact factor: 4.965

7.  Ethics of phase 1 oncology studies: reexamining the arguments and data.

Authors:  Manish Agrawal; Ezekiel J Emanuel
Journal:  JAMA       Date:  2003-08-27       Impact factor: 56.272

8.  Informed consent for phase I studies: evaluation of quantity and quality of information provided to patients.

Authors:  M Tomamichel; C Sessa; S Herzig; J de Jong; O Pagani; Y Willems; F Cavalli
Journal:  Ann Oncol       Date:  1995-04       Impact factor: 32.976

9.  An intervention to improve cancer patients' understanding of early-phase clinical trials.

Authors:  Nancy E Kass; Jeremy Sugarman; Amy M Medley; Linda A Fogarty; Holly A Taylor; Christopher K Daugherty; Mark R Emerson; Steven N Goodman; Fay J Hlubocky; Herbert I Hurwitz; Michael Carducci; Annallys Goodwin-Landher
Journal:  IRB       Date:  2009 May-Jun

10.  Clinician and cancer patient views on patient participation in treatment decision-making: a quantitative and qualitative exploration.

Authors:  A H Pieterse; M C M Baas-Thijssen; C A M Marijnen; A M Stiggelbout
Journal:  Br J Cancer       Date:  2008-09-16       Impact factor: 7.640
  10 in total
  5 in total

1.  Reply to Helping patients to understand terrifying news: Addressing the inner lives of physicians and extending beyond what we know.

Authors:  Gavin Paul Campbell; Eli Rowe Abernethy; Rebecca D Pentz
Journal:  Cancer       Date:  2020-02-19       Impact factor: 6.860

2.  Why many oncologists fail to share accurate prognoses: They care deeply for their patients.

Authors:  Eli Rowe Abernethy; Gavin Paul Campbell; Rebecca D Pentz
Journal:  Cancer       Date:  2019-11-27       Impact factor: 6.860

3.  Evaluating the impact of the Patient Preference Assessment Tool on clinicians' recommendations for phase I oncology clinical trials.

Authors:  Rachel S Hianik; Taofeek Owonikoko; Jeffrey Switchenko; Margie D Dixon; Walid L Shaib; Rebecca D Pentz
Journal:  Psychooncology       Date:  2021-05-31       Impact factor: 3.894

4.  Description of the types and content of phase 1 clinical trial consent conversations in practice.

Authors:  Louisa Wall; Zachary Luke Farmer; Margaret White Webb; Margie D Dixon; Ajay Nooka; Rebecca D Pentz
Journal:  Clin Trials       Date:  2015-08-28       Impact factor: 2.486

Review 5.  Advances in Treatment of Recurrent Small Cell Lung Cancer (SCLC): Insights for Optimizing Patient Outcomes from an Expert Roundtable Discussion.

Authors:  Millie Das; Sukhmani K Padda; Jared Weiss; Taofeek K Owonikoko
Journal:  Adv Ther       Date:  2021-09-26       Impact factor: 3.845
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.